![Edward Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edward Smith
Algemeen Directeur bij
Aristar Capital Management LLC
Vermogen: - $ op 31-05-2026
Profiel
Edward Byron Smith was the founder of Brightline Capital Management LLC, founded in 2005, where the title held was Managing Member from 2005 to 2014.
Current jobs include Executive Chairman at Population Bio, Inc.; Director at Elusys Therapeutics, Inc. since 2010; Director at Pelican Therapeutics, Inc.; Managing Member at Brightline Ventures I B LLC; Managing Member at Brightline Ventures.
I C LLC; Managing Member at Aristar Capital Management LLC since 2015; and Managing Member at Brightline Ventures.
I LLC.
Former jobs include Director, Chief Executive & Financial Officer at Agritech Worldwide, Inc. in 2017; Independent Director at Scorpius Holdings, Inc. from 2010 to 2026; Analyst at P&S Capital Partners LLC in 2004; Analyst at Credit Suisse First Boston LLC in 1998; and Associate at GTCR LLC in 2000.
Education includes an MBA from Harvard Business School conferred in 2003 and an undergraduate degree from Harvard College conferred in 1997.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-04-2025 | 0 ( -.--% ) | - $ | 31-05-2026 |
Actieve functies van Edward Smith
| Bedrijven | Functie | Begin |
|---|---|---|
Brightline Ventures I LLC | Corporate Officer/Principal | - |
Brightline Ventures I B LLC | Corporate Officer/Principal | - |
Brightline Ventures I C LLC | Corporate Officer/Principal | - |
Aristar Capital Management LLC
 Aristar Capital Management LLC Investment ManagersFinance Aristar Capital Mgmt invests in companies located in the United States. The firm focuses on a broad range of sectors and industries. It participates in early stage capital requirements. | Algemeen Directeur | 01-01-2015 |
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic biological agents for immuno-oncology combinations | Directeur/Bestuurslid | - |
Population Bio, Inc.
 Population Bio, Inc. Medical SpecialtiesHealth Technology Develops therapies and diagnostics | Voorzitter | - |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. BiotechnologyHealth Technology Develops immune-stimulatory and immune-derived therapies for the treatment of infectious diseases | Directeur/Bestuurslid | 01-11-2010 |
Eerdere bekende functies van Edward Smith
| Bedrijven | Functie | Einde |
|---|---|---|
| SCORPIUS HOLDINGS, INC. | Directeur/Bestuurslid | 23-04-2026 |
| AGRITECH WORLDWIDE, INC. | Algemeen Directeur | 14-07-2017 |
| ░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Edward Smith
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
53
Eerstegraads connecties
15
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 15 |
|---|---|
Agritech Worldwide, Inc.
 Agritech Worldwide, Inc. Food: Major DiversifiedConsumer Non-Durables Manufactures multifunctional dietary fiber ingredients for the food industry | Consumer Non-Durables |
P&S Capital Partners LLC
 P&S Capital Partners LLC Investment ManagersFinance P&S Capital Partners invests primarily in the stocks of US small- cap and large-cap companies in the utilities, consumer services, producer manufacturing and consumer durables sectors. The firm tends to acquire assets that are trading at a low price-to-earnings multiple compared to a stock's intrinsic value. P&S Capital Partners maintains a very high turnover rate. The Gracie Credit Opportunities Fund is a hedge fund that invests globally in investment grade fixed-income securities including high-yield, stressed and distressed credits. The Fund employs a fixed-income long/short investment strategy. | Finance |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. BiotechnologyHealth Technology Develops immune-stimulatory and immune-derived therapies for the treatment of infectious diseases | Health Technology |
Credit Suisse First Boston LLC
 Credit Suisse First Boston LLC Investment Banks/BrokersFinance Provides global investment banking services | Finance |
Scorpius Holdings, Inc.
 Scorpius Holdings, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of therapies | Health Technology |
Population Bio, Inc.
Population Bio, Inc. Medical SpecialtiesHealth Technology Develops therapies and diagnostics | Health Technology |
Brightline Ventures I B LLC | |
Brightline Ventures I C LLC | |
Pelican Therapeutics, Inc.
Pelican Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic biological agents for immuno-oncology combinations | Health Technology |
Aristar Capital Management LLC
Aristar Capital Management LLC Investment ManagersFinance Aristar Capital Mgmt invests in companies located in the United States. The firm focuses on a broad range of sectors and industries. It participates in early stage capital requirements. | Finance |
GTCR LLC
 GTCR LLC Investment ManagersFinance GTCR invests in companies located in North America. The firm focuses on financial services & technology, healthcare, information services & technology, TMT and business service sectors. It provides financing in the form of equity for corporate carve-outs, add-on acquisitions, buyouts and growth transactions with an investment size of USD 250 – 600 million. The firm also acquires minority interests. | Finance |
Brightline Capital Management LLC
 Brightline Capital Management LLC Investment ManagersFinance Brightline’s overall investment philosophy is value-driven and based on disciplined, rigorous fundamental analysis and research. The firm generally looks for companies with strong fundamentals that are selling at prices that represent a discount to our conservative estimate of the company’s long-run cash flows. They primarily invest with a bottom-up perspective, focusing on the individual company business model. Most investments have historically been made through US financial markets in US-based companies. Their investment strategy is focused on generating superior absolute returns. | Finance |
Brightline Ventures I LLC | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
